Physician profile
Arvind K Doshi
NPI 1457302259
$3,467.16
in general payments reported to CMS, 2019-2025
29 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $165 · 2021: $440 · 2022: $669 · 2023: $430 · 2024: $595 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $825.19 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $392.29 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $305.44 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $264.87 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.95 | 2021-2024 | Xifaxan, Trulance, Cycloset |
| Amgen INC. | $178.11 | 2021-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $126.64 | 2019-2023 | |
| Abbvie INC. | $110.04 | 2021-2022 | |
| Allergan, INC. | $109.55 | 2019 | |
| Phathom Pharmaceuticals, INC. | $108.89 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $71.93 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $70.66 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $68.18 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.13 | 2019-2024 | Jardiance, Synjardy |
| Exact Sciences Corporation | $63.65 | 2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $60.70 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $58.95 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $52.78 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $49.75 | 2022 | |
| Arbor Pharmaceuticals, INC. | $43.71 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.15 | 2019 | |
| Sanofi Pasteur INC. | $40.43 | 2019 | |
| Daiichi Sankyo INC. | $26.50 | 2019-2022 | |
| Amarin Pharma, INC. | $22.85 | 2019-2021 | |
| Renalytix Ai, INC. | $19.65 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Ermi LLC | $16.74 | 2019 | |
| Abbott Laboratories | $13.55 | 2021 | |
| Dexcom, INC. | $12.32 | 2022 | |
| Xeris Pharmaceuticals, INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.